Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

被引：37
|
作者：
Isakoff, Steven J. [1 ]
Baselga, Jose [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; PERTUZUMAB; LAPATINIB; EFFICACY; THERAPY; COMPLEX;
D O I：
10.1200/JCO.2010.31.6679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [21] Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
    Fang, Yan
    Wang, Zheng
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Zhu, Li
    Chen, Weiguo
    Li, Yafen
    Chen, Xiaosong
    Shen, Kunwei
    JOURNAL OF CANCER, 2020, 11 (09): : 2602 - 2609
  • [22] Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
    Larionov, Alexey A.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [23] Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
    Ohzawa, Hideyuki
    Sakatani, Takashi
    Niki, Toshiro
    Yasuda, Yoshikazu
    Hozumi, Yasuo
    BREAST CANCER, 2014, 21 (05) : 563 - 570
  • [24] Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
    Yu, Tosol
    Cho, Bong Jun
    Choi, Eun Jung
    Park, Ji Min
    Kim, Dan Hyo
    Kim, In Ah
    ONCOTARGET, 2016, 7 (48) : 79075 - 79086
  • [25] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome
    Krell, Jonathan
    James, Colin R.
    Shah, Deep
    Gojis, Ondrej
    Lim, Adrian
    Riddle, Pippa
    Ahmad, Riz
    Makris, Andreas
    Cowdray, Andrew
    Chow, Angela
    Babayev, Tamerlan
    Madden, Peter
    Leonard, Robert
    Cleator, Susan
    Palmieri, Carlo
    CLINICAL BREAST CANCER, 2011, 11 (03) : 153 - 160
  • [26] Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo
    Liu, Weihua
    Xu, Jinmei
    Liu, Yilun
    Yu, Xiaoping
    Tang, Xi
    Wang, Zhi
    Li, Xin
    MOLECULAR MEDICINE REPORTS, 2014, 10 (04) : 1921 - 1926
  • [27] Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer
    Patel, Kiki
    Hageman, Kelly
    Cooper, Maryann
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (07) : 537 - 548
  • [28] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
    Burris, Howard A., III
    Rugo, Hope S.
    Vukelja, Svetislava J.
    Vogel, Charles L.
    Borson, Rachel A.
    Limentani, Steven
    Tan-Chiu, Elizabeth
    Krop, Ian E.
    Michaelson, Richard A.
    Girish, Sandhya
    Amler, Lukas
    Zheng, Maoxia
    Chu, Yu-Waye
    Klencke, Barbara
    O'Shaughnessy, Joyce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 398 - 405
  • [29] Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight
    Lin, Nancy U.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 251 - 253
  • [30] Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial
    Lang, I.
    Bell, R.
    Feng, F. Y.
    Lopez, R. I.
    Jassem, J.
    Semiglazov, V.
    Al-Sakaff, N.
    Heinzmann, D.
    Chang, J.
    CLINICAL ONCOLOGY, 2014, 26 (02) : 81 - 89
12345